Cytokine release syndrome

This early-phase trial tests whether giving siltuximab before epcoritamab can prevent cytokine release syndrome (CRS), a common and sometimes severe side effect. About 20 adults with non-Hodgkin lymphoma will receive siltuximab one hour before their first epcoritamab dose. Resear…

This study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …

This study tests a new way of giving the drug elranatamab to people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if giving the drug less often and outside the hospital can reduce side effects and hospital stays. About 40 a…

This early-stage trial tests a new drug called PRS CK STORM, made from a mix of immune and fat cells, to see if it can safely calm the 'cytokine storm'—a dangerous overreaction of the immune system—in people with severe lung infections from COVID-19, flu, or RSV. The study will e…

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This early-phase trial tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving stem cell transplants from half-matched donors. About 41 adults with blood cancers will take these drugs aroun…

This phase 2 trial is testing whether two drugs, teclistamab and talquetamab, can be given safely in an outpatient setting for people with multiple myeloma. The study will enroll 100 participants who have already tried other treatments. The main goal is to see how often side effe…

This study tests a drug called CTO1681 in 54 adults with diffuse large B-cell lymphoma who are about to receive CAR-T therapy. The drug is taken three times daily for 15 days to prevent or reduce cytokine release syndrome, a potentially severe immune reaction. Researchers will mo…

This study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…

This early-phase study tests whether an investigational drug called Tadekinig alfa can safely and feasibly treat severe immune overreactions (CRS and HLH-like syndrome) that can occur after CAR T cell therapy. Ten adult participants who are already in a CAR T cell trial will rece…

This early-phase trial tests whether methylene blue, a dye used in medicine for other conditions, can safely treat two serious side effects of certain cancer immunotherapies: cytokine release syndrome (CRS) and immune-related neurotoxicity (ICANS). The study will enroll 18 adults…

This study tests a home-based telerehabilitation program for adults with lymphoma or myeloma who have received CAR-T cell therapy. Participants use a tablet or VR headset, along with a pulse oximeter and Fitbit, to follow personalized exercise and nutrition plans. The goal is to …

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study aims to find early signs that a patient is developing serious complications, like cytokine release syndrome, after immunotherapy for blood cancer. Researchers will track vital signs and immune responses in 100 adults receiving CAR-T or bispecific antibody therapy. The …

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study aims to understand why some adults develop secondary hemophagocytic lymphohistiocytosis (sHLH), a serious immune condition causing fevers and organ damage. Researchers will follow 300 participants for up to 3 years, collecting blood samples and medical data to identify…

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…

This registry is tracking 3,000 critically ill patients who receive the CytoSorb blood-filtering device in real-world intensive care settings. The goal is to collect data on how the device is used and whether it relates to patient survival. It covers many conditions like sepsis, …